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Islet transplantation is an attractive treatment for selected patients with brittle type 1 diabetes. In the clinical setting, intraportal
transplantation predominates. However, due to extensive early islet cell death, the quantity of islets needed to restore glucose
homeostasis requires in general a minimum of two donors. Moreover, the deterioration of islet function over time results in
few insulin-independent patients after ﬁve-year followup. Speciﬁc obstacles to the success of islet transplantation include site-
speciﬁc concerns for the liver such as the instant blood mediated inﬂammatory reaction, islet lipotoxicity, low oxygen tension, and
poor revascularization, impediments that have led to the developing interest for alternative implantation sites over recent years.
Within preclinical settings, several alternative sites have now been investigated and proven favorable in various aspects. Muscle is
considered a very promising site and has physiologically properties and technical advantages that could make it optimal for islet
transplantation.
1.Introduction
Type 1 diabetes mellitus is a chronic disease with typical on-
set during childhood or adolescence. Patients suﬀering from
the disease require multiple daily insulin injections coordi-
nated alongside vigilant monitoring of blood glucose levels.
For some patients, glucose homeostasis is not optimized de-
spite these eﬀorts, leading to repeated hyperglycemic and
hypoglycemic events. Such repeated episodes of severe hypo-
glycemia, requiring medical assistance, predicate a patient
being considered for islet transplantation. Currently, intra-
portaltransplantationisperformedinthemajorityofclinical
cases. The liver was selected as the optimal implantation site
for islet transplantation in the beginning of the 1970s, the
basis of experimental studies by Kemp et al. [1]. However,
clinical results of islet transplantation were meager with less
than 10% of transplant recipients displaying insulin inde-
pendency. The introduction of the Edmonton-protocol ten
years ago drastically improved the outcome to a rate of 80%
insulin independency after one year [2]. Nevertheless, this
procedure requires the islets of multiple donors and pro-
vides inadequate long-term results. Only 10% of transplant
recipients have maintained insulin-independency after ﬁve
yearsdespitecontinuingeﬀorts[3].Fundamentally,however,
intraportal transplantation must be considered successful.
The main stimulus for islet transplantation, repeat episodes
of severe hypoglycemia, is prevented in most patients irre-
spective of insulin independence after transplantation and
results in a marked increase in the quality of life.
During recent years, interest in alternative implantation
sites with the potential to improve long-term results has pro-
duced advances in noninvasive methodologies towards the
quantiﬁcation of islet graft mass and function. Positron
emission tomography (PET) is one such technique, provid-
ing a functional imaging modality that quantiﬁes an in vivo
distribution of bioactive compounds labeled with positron-
emitting nuclides. Commonly, clinically used PET tracers are
labeled with short-lived radionuclides that result in a radi-
ation dose that is both localized and nontoxic, allowing for
multiple scans of a single patient.2 Journal of Transplantation
2. Obstacles with Intraportal
Islet Transplantation
The rapid islet cell death observed in intraportal trans-
plantation is in part caused by an instant blood-mediated
inﬂammatory response (IBMIR) [4, 5]. The IBMIR consists
of both thrombotic and complement activation cascades
which lead to the formation of blood clots around the islets,
leucocyte inﬁltration, and disruption of islet morphology
[6]. In clinical settings, the IBMIR can be detected imme-
diately after islet infusion as an increase in both thrombin-
antithrombin complexes and increased c-peptide levels due
to beta-cell disruption and death [5]. With a combined pos-
i t r o ne m i s s i o nt o m o g r a p h ya n dc o m p u t e dt o m o g r a p h y
(PET/CT) technique, the early cell death after intraportal
islet transplantation has been estimated at approximately
25% [7].
In conjunction to the IBMIR, characteristic hypoxic
events have also been contributed to early islet cell death.
Indeed, during the process of initial islet isolation, the native
vascular connections are disrupted, enforcing the islets to
depend on oxygen diﬀusion immediately after transplanta-
tion. This process is further complicated when considering
that the liver parenchyma has a much lower oxygen tension
than can be found in the pancreas [8]. We recently observed
in an experimental animal model that approximately 70% of
islets are hypoxic one day after intraportal transplantation
[9].Thisﬁndingwasaccomplishedemployingpimonidazole,
a biochemical marker that accumulates in islet cells with
oxygentensionlevelsbelow7.5–10mmHg.Notably,thehyp-
oxia may even be underestimated in these experiments, as
pimonidazole adducts are not incorporated within dead or
dying cells. In addition, our team has also observed that
caspase-3 staining of islets reveals an apoptosis level, corre-
lating to the hypoxia, as high as 10% in islets one day after
intraportal transplantation [10].
It has been proposed that the high concentrations of
immunosuppressive drugs in the portal vein, following in-
testinal uptake of the drugs, may have a toxic eﬀect on trans-
plantedisletcellsintheliver[11,12].Moreover,severallong-
term liver-site-speciﬁc challenges have been identiﬁed such
as lipotoxicity to the transplanted cells [13, 14] and insuﬃ-
cient vascular engraftment [15, 16]. Intrahepatically trans-
planted islets are slowly revascularized, severely impairing
blood perfusion and oxygenation up to three months after
transplantation [17]. Considering the aforementioned chal-
lenges,substantialhurdlesremaintobeovercometoimprove
the long-term prognosis of existing intraportal islet trans-
plantation procedures.
3. Considerations for a New Implantation Site
Over the last decade, there has been an increased interest in
alternative implantation sites due to the identiﬁed obstacles
and the deterioration of islet graft function after time follow-
ing intraportal transplantation. Several factors must be con-
sidered when choosing an optimal implantation site. The
prospective organ requires physiological characteristics that
are favorable for islets in regards to oxygen tension, vascular
supply,andangiogenesis.Implantedbetacellsmustalsohave
thecapacitytoadapttotheimplantationorganandmaintain
their diﬀerentiation. Furthermore, a viable route for insulin
secretionandglycemicdetectionisrequired.Somesites,such
as the testis, thymus, brain, and eye are immune-privileged
makingthemtemptingcandidates.Consideringthetechnical
and surgical aspects, an ideal site should have easy access,
allowing for a minimally invasive procedure. Preferably, it
should be possible to obtain biopsies without causing undue
risk to either the patient or the graft. There is current opti-
mism towards developing methods able to quantify the islet
cell mass with imaging techniques. Several PET probes in-
tendedfornoninvasivevisualizationofendogenousbetacells
in the pancreas have been investigated during recent years,
generally targeting the monoamine pathways as these are
absent in exocrine tissue which compose the vast majority
(>95%)ofthepancreaticvolume.PETtracershavebeenutil-
izedforstudiesofthecentralnervoussystem(CNS)sincethe
1980s, in particular for the serotonergic and dopaminergic
systems, although various tracers have now been applied to
image endogenous beta cells. These include carbon-11, ﬂuo-
rine-18, or gallium-68 labeled versions of small molecule
ligandsorpeptides,targetingvesicularmonoaminetransport
[18] and oxidation as well as serotonin and dopamine syn-
thesis [19, 20]. Other recently available PET tracers act as
ligands for beta cell-speciﬁc markers such as sulfonylurea re-
ceptor-1 [21] and glucagon-like peptide-1 receptor [22]. It
has also been suggested that early beta cell destruction due
to autoimmunity or rejection can be studied by [18F]FDG, a
marker for glucose metabolism, imaging both inﬂammatory
lesions and insulitis [23]. Technical advances which image
endogenous beta cell mass can naturally be applied in islet
transplantation studies.
The pancreas is a tempting implantation site. It is the
natural milieu for islets. In experimental studies we have
shown that the vascular density in islets transplanted to the
pancreasisonlyslightlylowerthaninendogenousislets[24].
Wehavealsoshownthatincontrasttointrahepaticallytrans-
planted islets, islets transplanted to the pancreas display less
severe changes in gene expression and have only moderate
changes in their metabolic function posttransplantation
[25]. However, injection into the pancreas may elicit leakage
of exocrine enzymes, resulting in pancreatitis. Therefore, the
pancreas has rarely been considered as a clinically feasible
implantation site. Improved implantation techniques, for
example,beneath thepancreatic capsule,aswellassafetyand
eﬃcacy studies in large animal models are clearly needed
before considering clinical trials.
Superior islet survival has recently been demonstrated
following experimental transplantation into the oment when
compared to intraportal islet transplantation [26]. Since the
1980s, the omental pouch has been considered as a potential
site for islet transplantation [27]. A primate model study re-
vealed an observable delay in transplant engraftment when
compared to intraportal transplantation, yet over time, re-
cipients obtained equitable plasma C-peptide levels [28].
Although the vascular engraftment of islets in oment is de-
layed, the omentum or omental pouch has the capacity to be
a useful clinical site.Journal of Transplantation 3
The anterior chamber of the eye provides excellent con-
ditions for engraftment of transplanted islets [29]. Injected
islets engraft on the iris become fully revascularized and
have the capacity to reverse diabetes in mice [29]. A recent
follow-up study in diabetic baboons also showed successful
long-term survival and function of islets after allogeneic
transplantation [30]. Furthermore, transplanted islets con-
tributed to glycemic control without any perceived impair-
ment of vision. The implantation procedure was minimally
invasive, and considering the immune-privileged properties
ofthissite,itcanbeconcludedasanattractivesiteforclinical
use. However, pertinent safety and eﬃcacy studies remain,
bearinginmindthepotentialimpactontransplantrecipients
visual function if transplanting islets of a suﬃcient magni-
tude to reverse hyperglycemia.
4.IntramuscularIslet Transplantation:
A PromisingImplantationSite
Striatedmusclehasbeenusedfordecadesasasiteforautolo-
goustransplantationofnormalparathyroidtissueinpatients
with hyperparathyroidism, with excellent results [31]. Such
grafts have proven highly functional for more than 10 years,
with full restoration of calcium homeostasis [31]. The proce-
dure is well documented with few complications and is con-
sidered a standard technique.
Muscle has a naturally occurring angiogenesis with a
higher oxygen tension than can be found in the liver paren-
chyma. We have recently shown that there is a rapid revas-
cularization of intramuscularly transplanted mouse and hu-
man islets, containing a blood vessel incidence on par with
nativeisletswithintwoweeksposttransplantation[32].Graft
blood perfusion was restored and the oxygen tension of in-
tramuscular islets only slightly diminished compared to na-
tive islets after revascularization [33]. This paradigm is fur-
ther supported in the clinical setting and witnessed through
magnetic resonance imaging of pancreatectomized patients
receiving autotransplantation of isolated islets to the bra-
chioradialis muscle, where a high revascularization of intra-
muscular islet grafts has also been observed [32]. Experi-
mentally, islets transplanted to muscle also have a superior
glucose tolerance compared to recipients of similar numbers
of islets transplanted intraportally [32]. A case report from
the Nordic Network for Clinical Islet Transplantation, where
a young patient with hereditary pancreatitis underwent total
pancreatectomy treated by an autologous islet transplant to
the brachioradialis muscle, also showed sustained insulin
production from the graft for more than two years [34].
However, it is arguably the implantation technique itself
that is pivotal to a high success rate at the intramuscular site.
Injection of large clusters of islets causes substantial early
islet cell death due to hypoxia. In such grafts, massive ﬁbrosis
can be observed both experimentally and clinically [32, 33]
(Figure 1). This could explain the previous erratic success in
experimental and clinical intramuscular islet transplantation
[35–37]. It had become apparent to our group that in order
to improve early islet survival, a shift in the transplantation
procedure was required that disperses the islets throughout
thetissue,forexample,transplantingtheisletsalonga“pearls
Intramuscular islet transplantation
Revascularization, oxygen tension, minimal
invasive, imaging and biopsies
Hypoxia and ﬁbrosis
Figure 1: Summary of beneﬁcial aspects and known obstacles for
intramuscular islet transplantation.
on a string” fashion. Early cell death might be further re-
duced by remodeling the transplant site with bioengineered
matrices and/or cotransplantation of oxygen carriers such as
perﬂuorocarbons. There is also the possibility of improving
the vascular network in the muscle prior to transplantation,
since higher vascular density could easily be induced by an-
giogenic stimulators or hypoxia, both of which have a strong
stimulatory eﬀect on angiogenesis in muscle [38].
Duetominimalislet-bloodcontactwithinintramuscular
transplantation, the challenge presented by the IBMIR is
reduced. The capacity to transplant islets into a designated
areainthemusclealsofacilitatessiteremodelingofimmuno-
logicaleventspriortotransplantation.Speciﬁcally,thiscould
include modulation of early inﬂammation with mesenchy-
mal stem cells, providing the potential to accelerate revascu-
larization, as shown in both intraportal islet transplantation
[39, 40] and islets transplanted beneath the kidney capsule
[41]. Mesenchymal stem cells could either be cotransplanted
or injected in advance to modulate the site.
It has earlier been reported that even moderate exercise
causes hypoglycemia in rats with islets transplanted to the
liver,kidney,andperitonealcavity[42].Hypoglycemicevents
can also be observed following intrapancreatic transplan-
tation of islets [43]. Upregulation of lactate dehydrogenase
in transplanted islets, with concomitantly increased lactate
production eliciting insulin release during periods of low
blood glucose levels, may be an explanation for this [25, 44].
It has not yet been reported how lactate dehydrogenase levels
and other gene expression are aﬀected in betacells of intra-
muscular islet grafts. Exercise might also cause a site-speciﬁc
challenge to intramuscular islet grafts due to intramuscular
pressure changes, since the glucose-consumption of muscle
cells increases during exercise in accord with the regional
blood ﬂow.
5. Monitoringof Islets atthe
IntramuscularSite
It is diﬃcult to obtain biopsies of islets transplanted into
the liver. Islets are spread throughout the liver parenchyma,
and liver biopsies per se are not free of risk. However, in the
muscle, a biopsy would be simple to obtain. Preemptively
dividing the transplanted islet mass, designating a speciﬁc
islet mass to a separate site intended for potential biopsies,
would allow subsequent studies to identify early markers for
rejection.
The feasibility of imaging transplanted islets through
PET techniques depends to a large extent on the site of im-4 Journal of Transplantation
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Figure 2: PET imaging of intramuscularly transplanted islets using the VMAT2 ligand [18F]FE-DTBZ-d4 as PET tracer. An inbred C57BL/6
mouse was transplanted with 300 mouse islets to the left abdominal muscle. The islets were labeled with Q-tracker prior to implantation.
One month later, the mouse was administered the PET tracer [18F]FE-DTBZ-d4 intravenously. The tracer uptake could be detected by a
μPET/CT scanner after 60 minutes (right image, orange delineation). The corresponding location of the islets as determined by Q-tracker
ﬂuorescence emission is shown to the left.
plantation. This can be understood by examining the com-
position of a PET tracer signal emitted within a given region
in vivo. In the main, a signal containing a composite of spe-
cific binding is produced (i), or the PET probe bound to
the receptor of interest is proportional to receptor density.
Displaying nonspeciﬁc binding (ii), the PET probe may also
bindtootherstructures,revealingvascularcontribution(iii).
Vascular contribution is vital, as the tissue uptake of tracer is
limited by local perfusion, potentiating an underestimation
of uptake in grafts with low revascularization. All of these
factors inﬂuence our ability to study islet grafts in diﬀerent
tissues.
With these issues in mind, we can see that longitudinal
noninvasive visualization of hepatic grafts presents a consid-
erable challenge, with substantial graft dilution (i). In addi-
tion, it is diﬃcult to design PET tracers with a low hepatic
background signal. Most tracers are metabolized in the liver
(ii). The perfusion (iii), however, is suﬃcient to transport
the tracer to engrafted islets in hepatic sinusoids shortly after
transplantation.
This paradigm is reversed when considering intramus-
cular islet grafts. Grafts are generally pure and concentrated
(i), with the above-mentioned PET tracers eﬀecting a low to
negligible uptake in muscle tissue (ii). Revascularization is
therefore the limiting factor for visualization of the graft. It
has recently been shown that intramuscular islet grafts attain
a vascularization comparable to that in pancreatic islets after
approximately 2 weeks [32]. Considering these illustrations,
quantiﬁcation of intramuscular islet grafts containing an ad-
equate volume is potentially achievable after engraftment
and revascularization has been completed.
Progress with visualizing has been made both in preclin-
ical and clinical studies of intrahepatic and intramuscularly
transplanted islets using PET. The hepatic distribution and
survival of islets during the peritransplant phase, following
intraportal islet transplantation, has been studied with ex
vivo labeling of islets by [18F]FDG prior to infusion in mu-
rine [45] and porcine [46] models as well as in the clinic [7].
However, longitudinal studies are not yet possible using the
ex vivo labeling methodology.
Uptake in an intramuscular islet graft of a vesicular mo-
noamine transporter 2-(VMAT2-) ligand, [11C]DTBZ, cor-
related well to the observable decrease in blood sugar of a
preclinical STZ mouse model in a study by Witkowski et al.
[47]. However, interpretation of the results and translation
to the clinical situation is problematic when considering that
the islets were implanted using a bioscaﬀold.
Pattou et al. [48] showed proof-of-principle in the clinic
by visualizing islets transplanted to the brachioradialis mus-
cle in a type 1 diabetic patient by intravenous administration
of a [111In]-labeled exendin-4, a GLP-1R ligand, using
SPECT, an imaging modality related to PET.
The VMAT2 ligand [18F]FE-DTBZ-d4 (see Figure 2)a n d
thecatecholamineprecursor[ 18F]L-DOPA(unpublisheddata)Journal of Transplantation 5
are currently being investigated as biomarkers for trans-
planted beta cells in two ongoing preclinical studies of intra-
muscularly transplanted islets in mice.
6. Conclusions
Striated muscle is a promising implantation site and in many
regards superior to the liver. However, it is not yet fully char-
acterized regarding islet long-term survival and functional-
ity. The obstacles with early islet cell death observed to date
following intramuscular islet transplantation can likely be
overcome through remodeling the implantation site. Further
studies capable of actualizing eﬀective strategies are clearly
needed, within both small and large animal models.
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